Relevance of
Intellectual
Property |
|
Intellectual
Property is like any other property and the developed
countries respect and comply with Intellectual Property
India has to do the same. Historically, India was the
seat of knowledge and wisdom, and India was the leader
in most disciplines. Nalanda and Takshila were the seats
of wisdom...
More Details...
|
|
Markets |
|
Regulated Markets
(USA, EUROPE)
Non-Regulated
(SOUTH EAST, ASIA, AFRICA, LATIN
AMERICA, CIS ETC)
|
|
| |
WHO-GMP
Approved
manufacturing facilities |
 |
|
WHO-GMP Approved manufacturing
facilities for Oncology, General tablets and
cephalosporin
|
|
| |
|
|
|
Intellectual Property
Nano Silver Gel -
KLab has received Drugs Controller General of India approval for its Nano Silver Gel for manufacturing and marketing in India for burns and wounds.
KLab has also got a product patent granted for India.
Cefixime - KLab has a product and process patent for Cefixime + Cloxacillin + Lactobacillus, Cefixime OD and Cefixime with Flavonoid for India and Internationally.
Methocarbamol (Skeletal Muscle Relaxant) -
KLab has received a process and product patent for Methocarbamol
with Nimesulide Tablet, Diclofenac Tablet, Nimesulide Dispersible Tablet and Diclofenac Gel for India.
Prenoxdiazine tablets (Antitussive) - KLab has
received a product and process Patent for India.
Glycopyrrolate tablets - KLab has received
process and a product patent for India.
Etoricoxib & Paracetamol tablets-
KLab has received a process and product patent for India.
Methotrexate Gel -
KLab has received a process and product patent for for India.
Manufacturing / Licensing Agreements
KLab has sold its Anafortan Trademark and Cefi Trademark to M/s. NPIL.
kLab has given NPIL an exclusive right to use their
patents for camylofin injections, camylofin & paracetamol tablets
and camylofin & paracetamol suspension / drops for the Indian
market. KLab has given NPIL the exclusive right to use their
patents camylofin & diclofinac injection and tablet for the Indian
market up to Nov 09. KLab has given NPIL the non exclusive
rights of its patent of cefixime, cloxacilin with Lactobacillus and
cefixime OD tablets.
KLab has reached a manufacuturng supply agreement with M/s. Unimark,
M/s. Zuventus, M/s Emcure, M/s Wockhardt, M/s Cadila, M/s
Glenmark, M/s Intas etc.. for oncology formulations
KLab has reached a licensing agreement with M/s. BDR Pharmaceuticals Int’l. Pvt. Ltd. for manufacturing Liposomal Doxorubicin
Cefi XL was the No.1
new product launched in India
Cefi XL was the No. 1 new product, out of all new
products launched in India in last 24 months as per IMS
ORG July 2006 .
Cefi XL is patented in India & Europe. US
patent grant is awaited.
Cefi XL (Cefixime + Cloxacillin +
Lactobacillus
Has been sold to M/s. NPIL and Product Patent licensed non exclusively to M/s. NPIL. Also licensed to M/s. Hetero and M/s. Wockhardt. Litigation still pending against M/s. Mankind, M/s.
Macleod, M/s. Intas, M/s. FDC and M/s. Allembic.
Marketing Infrastructure expanded in India
Klab's 750 Medical Representatives,150 managers who meet 140,000 Doctors and
56000 Pharmacies every month, with special focus on
Gastroenterologists, General Surgeons, Gynaecologists,
Orthopedic Surgeons, Pediatricians, Physicians and
Oncologists.
K-CHIRAL’S.
KLab has developed multifunctional Chiral Pools of
Carbohydrates, Monosaccharides, Amino Alcohols, Oxazolidinones etc
K-Dendrimers.
KLab is developing an
economical dendrimer system for cosmetic applications and drug
delivery.
KLab has filed for several patents using dendrimers as a delivery platform.
K-NDDS
KLab has filed several
patents for site specific deliveries
|
 "
In the Court Of Shri Manoj Kumar jain,
Additional District Judge , Delhi
M/s. Wisdom Pharma have recognized and acknowledged
M/s. Khandelwal Laboratories Pvt. Ltd / Mr. Sanjeev
Khandelwal to be the owner of the
Registered Patent No.197822 and have undertaken to this Hon'ble Court not to challenge the proprietary rights
of this patent at any point of time before any
Hon'ble Court / Tribunal and or any other statutory
body."
|
|
| |
|
|
| |
|
|
| |
|
